Piramal Pharma reported a net loss of ₹326 crore for FY2026 on revenues of ₹8,869 crore. The company cited inventory destocking and softer order inflows as reasons for this transitional year, expecting a rebound in FY2027.
Piramal Pharma Reports FY2026 Net Loss Amidst Transitional Year
Piramal Pharma Limited reported a consolidated net loss of ₹(325.94) crore for the fiscal year 2026, on revenues of ₹8,869.08 crore.
Reader Takeaway: Revenue decline pressured margins, but strategic buys and capex signal future growth.
What just happened
Piramal Pharma recorded a consolidated revenue of ₹8,869.08 crore in FY2026, a decrease from ₹9,151.18 crore in FY2025. The company posted a net loss of ₹(325.94) crore for FY2026, a significant shift from a profit of ₹91.13 crore in the previous fiscal year. Consolidated EBITDA also saw a decline, dropping to ₹1,134.92 crore from ₹1,579.64 crore.
Why this matters
The net loss and reduced revenue indicate current challenges within the company's operations. However, strategic acquisitions and continued capital expenditure suggest a long-term growth strategy. The board did not recommend any dividend for FY2026, indicating a focus on reinvesting earnings.
The backstory
FY2026 was characterized by inventory destocking and a slowdown in early-stage order inflows, particularly impacting the Contract Development and Manufacturing Organization (CDMO) business, which reported revenues of ₹4,915 crore. Despite these headwinds, the Consumer Healthcare (PCH) segment showed resilience with 17% revenue growth, bolstered by a 48% increase in e-commerce sales. The Critical Care (CHG) segment generated ₹2,703 crore in revenue.
What changes now
Piramal Pharma has completed capital expenditure of ₹890 crore, primarily for expanding capacity for sterile injectables and payload-linkers at its Lexington and Riverview facilities. The company also acquired Kenalog®, a branded injectable corticosteroid, from Bristol Myers Squibb. Net debt reduced to ₹4,163.82 crore as of March 31, 2026, down from ₹4,331.73 crore the previous year.
Risks to watch
Management's forecast for FY2027 hinges on the recovery of biopharma funding and increased M&A activity. Any continued softness in these areas could delay the anticipated return to broad-based revenue growth and margin expansion.
Peer comparison
While specific peer data for FY2026 is not provided in the filing, the performance of Piramal Pharma's Consumer Healthcare segment indicates strength in a competitive market. The CDMO segment's performance is subject to broader industry trends in R&D spending and outsourcing.
Context metrics (time-bound)
- FY2026 Revenue: ₹8,869.08 crore
- FY2025 Revenue: ₹9,151.18 crore
- FY2026 Net Loss: ₹(325.94) crore
- FY2025 Net Profit: ₹91.13 crore
- FY2026 Capex: ₹890 crore
- Net Debt as of March 31, 2026: ₹4,163.82 crore
What to track next
Investors will be keen to observe the impact of capacity expansions and the successful integration of the Kenalog® acquisition. Monitoring order inflows in the CDMO business and the broader biopharma funding environment will be crucial for assessing future performance.